Kisunla vs. Leqembi: Which Alzheimer's Treatment Is Right for Eligible Patients?

Choosing an Alzheimer's treatment can be challenging for patients and families, especially as newer medications introduce different approaches to managing the disease. Two treatments that have attracted attention are donanemab and lecanemab. Both target amyloid beta, a protein associated with Alzheimer's disease, but they differ in their dosing schedules, treatment protocols, and certain clinical considerations. Understanding these differences can help families prepare for informed discussions with their healthcare providers. Kisunla and Leqembi are prescription therapies designed for eligible individuals in the early symptomatic stages of Alzheimer's disease. Although both aim to slow cognitive decline, neither provides a cure or reverses existing brain damage. Exploring their similarities and differences is an important step toward understanding available treatment options.

Why Are These Two Alzheimer's Medications Compared?

Alzheimer's disease is a progressive neurological condition associated with changes in brain structure and function. Amyloid beta plaques are among the biological characteristics associated with the disease.

Traditional medications generally focus on managing symptoms, while newer disease-modifying therapies aim to influence underlying disease processes.

Both donanemab, marketed as Kisunla, and lecanemab, marketed as Leqembi, are monoclonal antibodies that target amyloid beta.

However, they recognize different forms of amyloid and have distinct treatment protocols. These differences can influence the practical experience of patients and the monitoring required during therapy.

How Do Kisunla and Leqembi Work?

Although both medications target amyloid beta, their mechanisms are not identical.

Understanding Donanemab

Donanemab is designed to recognize a modified form of amyloid beta associated with deposited plaques.

It helps the immune system identify and remove amyloid accumulation in the brain. Clinical studies have demonstrated that this approach can slow cognitive and functional decline in certain patients with early symptomatic Alzheimer's disease.

One notable feature is that treatment discontinuation may be considered after imaging demonstrates that amyloid plaque levels have reached minimal levels.

Understanding Lecanemab

Lecanemab targets soluble amyloid beta protofibrils, which are protein aggregates associated with Alzheimer's disease.

It also helps reduce amyloid accumulation through antibody-mediated activity.

Clinical research has demonstrated that lecanemab can modestly slow clinical decline in individuals with early Alzheimer's disease.

Unlike donanemab's plaque-based stopping approach, its standard treatment schedule generally involves ongoing administration.

Key Differences Between the Two Treatments

Understanding the practical differences can help patients and caregivers discuss their options with a neurologist.

Treatment consideration	Donanemab	Lecanemab
Brand name	Kisunla	Leqembi
Active ingredient	Donanemab	Lecanemab
Main target	Deposited amyloid plaques	Soluble amyloid beta protofibrils
Administration	Intravenous infusion	Intravenous infusion or approved maintenance options, depending on the treatment stage and formulation
Standard IV schedule	Every four weeks	Every two weeks initially
Potential stopping approach	May stop after PET-confirmed minimal plaque levels	Generally continued as ongoing therapy
Important safety concern	ARIA	ARIA

Both medications require careful patient selection, appropriate diagnostic confirmation, and ongoing medical supervision.

Comparing Treatment Schedules and Administration

The frequency of treatment can influence how patients and caregivers organize their schedules.

Donanemab Administration

The current labeled intravenous schedule begins with gradually increasing doses:

First infusion: 350 mg.
Second infusion: 700 mg.
Third infusion: 1,050 mg.
Fourth and subsequent infusions: 1,400 mg.

Infusions are generally administered every four weeks and take approximately 30 minutes.

Treatment may be discontinued in selected patients after amyloid PET imaging demonstrates sufficiently low plaque levels, according to the prescribing information.

Lecanemab Administration

The standard intravenous maintenance approach for lecanemab begins with infusions every two weeks.

Its treatment pathway may also involve an approved maintenance approach after the initial treatment period. The available options and schedules depend on the formulation and prescribing guidance.

These differences mean that the practical commitment can vary. Patients should discuss infusion frequency, transportation, follow-up requirements, and long-term treatment expectations before making a decision.

What About Treatment Effectiveness?

Both medications have demonstrated the ability to slow clinical decline in people with early symptomatic Alzheimer's disease.

However, comparing their effectiveness requires careful interpretation.

The clinical trials evaluated different patient populations, treatment periods, outcome measures, and study designs. Therefore, comparing percentages directly does not establish that one medication is more effective than the other.

For example, donanemab was evaluated in the TRAILBLAZER-ALZ 2 trial, while lecanemab was studied in the CLARITY AD trial.

Both studies reported statistically significant slowing of clinical decline compared with placebo in their respective study populations.

Neither medication stops Alzheimer's disease completely. Patients may continue experiencing changes in memory, reasoning, and daily functioning despite treatment.

The appropriate choice depends on individual medical circumstances rather than a simple comparison of trial percentages.

Comparing Side Effects and Safety Risks

Safety is one of the most important considerations when evaluating these treatments.

Both medications carry a risk of amyloid-related imaging abnormalities, commonly known as ARIA.

ARIA generally involves two categories:

ARIA-E: Brain swelling or fluid accumulation.
ARIA-H: Small areas of bleeding or blood-related deposits in the brain.

Some patients may develop these abnormalities without noticeable symptoms. Others may experience headaches, confusion, dizziness, visual changes, or difficulty walking.

Serious and potentially life-threatening complications can occur.

Both treatments require brain MRI monitoring. The exact imaging schedules and precautions differ according to their respective prescribing information.

Patients should also discuss APOE ε4 genetic testing, previous brain hemorrhages, blood-thinning medications, and other relevant medical conditions with their physicians.

Who May Be Eligible for Either Treatment?

Both medications are intended for individuals with early symptomatic Alzheimer's disease.

Generally, the indicated population includes patients with:

Mild cognitive impairment due to Alzheimer's disease.
Mild dementia due to Alzheimer's disease.
Confirmed amyloid pathology.
Medical circumstances that allow treatment and appropriate safety monitoring.

A diagnosis of dementia alone does not establish eligibility.

A neurological evaluation, cognitive assessment, medical history review, and amyloid confirmation are important parts of the selection process.

For patients considering Kisunla or Leqembi, physicians must also assess individual risks and discuss whether the potential benefits justify treatment.

Questions to Ask Before Choosing an Alzheimer's Medication

Patients and caregivers can make consultations more productive by preparing questions in advance.

Consider discussing:

Which treatment is appropriate for the patient's current stage of Alzheimer's disease?
What are the differences in infusion frequency and long-term treatment requirements?
How frequently will MRI examinations be necessary?
Does the patient's medical history increase the risk of ARIA?
What symptoms require immediate medical attention?
How will treatment progress and potential benefits be evaluated?

These discussions can help families understand the responsibilities associated with treatment and make decisions based on realistic expectations.

Conclusion

Comparing newer Alzheimer's medications involves understanding more than their ability to target amyloid beta. Kisunla and Leqembi offer different approaches to amyloid removal, administration schedules, and ongoing treatment considerations. Both have demonstrated modest benefits in slowing clinical decline among eligible individuals with early symptomatic Alzheimer's disease, but both also carry important safety risks, particularly ARIA. There is no universally appropriate choice for every patient. A comprehensive neurological assessment, discussion of personal risk factors, and understanding of treatment goals can help patients and families identify the most suitable option with guidance from a qualified healthcare professional.

Frequently Asked Questions

1. Are Kisunla and Leqembi chemotherapy medications?

No. Both are monoclonal antibody therapies designed to target amyloid beta associated with Alzheimer's disease. They are not chemotherapy drugs.

2. Can a patient switch from one treatment to the other?

A switch may be considered in certain clinical circumstances, but it requires specialist evaluation. Physicians must review previous treatment exposure, imaging results, potential risks, and the reason for changing therapies.

3. Do both medications require amyloid confirmation?

Yes. Both treatments require confirmation of amyloid pathology before initiation because their intended therapeutic targets are associated with amyloid accumulation.

4. Does a lower infusion frequency mean a treatment is more effective?

No. Administration frequency does not establish effectiveness. Treatment outcomes depend on clinical evidence, patient characteristics, safety considerations, and individual response.